Spleen Focus-Forming Virus in Friend and Rauscher Leukemia Virus Preparations 2
RECENT ADVANCES in the biochemistry (1) and immunology (2-4) of RNA tumor viruses have spurred a remarkable interest in these agents, and effective communications about them will require a thorough understanding of their biology and consis ten t use of a logical terminology (5) . This is especially needed for the murine leukemia viruses (MuLV's) isolated by Friend (6) and Rauscher (7), usually called simply Friend and Rauscher leukemIa viruses (F-MuLV and R-MuLV), respectively.
It is well established that Friend and Rauscher virus preparations are distinct from other MuL V's in the rapidity with which they induce hepatosplenomegaly and erythroleukemia in susceptible strains of mice infected as adults (6) (7) (8) (9) . Another property of Friend and Rauscher virus preparations is their capacity to induce macroscopic foci of primitive erythroid cells in the red pulp of the spleen (10, 11) . This property, which is unique to F-MuLV an.d R-MuLV, could be due to an acquired genetic change in a homogeneous virus population or to the presence of another virus in a heterogeneous vi:us population. Recent evidence (12) (13) (14) supportmg the latter alternative has shown that the spleen focusforming virus (SFFV) in Friend and Rauscher v~rus preparations is an entity distinct from the more typIcal MuL V's also present in these virus stocks, and that SFFV is defective and dependent on its associated MuL V for some still poorly understood helper function(s). Awareness of this complexity in F-MuLV and R-MuL V preparations should improv~ the interpretation of data obtained with these VIruses, as was achieved previously by awareness of the complexity of defective sarcoma vir~s preparations.
. The existence of SFFV in Fnend vIrus preparatIons was described in recent reviews on host genes which control MuLV expression (15, 16) . Emphasized h~rc arc the biologic properties of SFFV coIllpared WIth another more thoroughly characterized RNA tumor virus of mice, murine sarcoma virus (MuSV). Unless otherwise identified, SFFV will refer to Friend (F) and Rauscher (R) isolates, and the presence of MuLV helper can be assumed.
SIMILARITIES BETWEEN SFFV AND MuSV
Like MuSV (17) , but in contrast to all other MuLV's SFFV rapidly induces discrete foci of transformed ~ells, and the number of foci is related to the dose of virus administered (10, 11) . The standard 9-day assay based on this phenomenon involves ~he counting of foci in the red pulp of the spleen whIch have become sufficiently enlarged to be detected a~ the splenic surface with the unaide~ ey~. Some fOCI in the spleen undoubtedly escape thIS kmd of detection as do foci that arise in the bone marrow (18) , but the directly proportional ("one-hit") doseresponse relationship obser~ed with spleen. foc.us formation in susceptible mIce (see below) Imphes that the frequency of undetected foci remains relatively constant. The unit of vir~s titer for both MuSV and SFFV is the focus-formmg umt (FFU)-that amount of virus required to induce an average of one focus per scoring unit (petri dish or spleen, respectively).
. . . Titrations of SFFV m susceptible mouse strams generally give one-hit dose-response patt~:ns. (text- fig. lB, broken line) where the number off?clls directly proportional to the virus dose. From thIS. and many similar titrations, it appears that SFFV IS t.he ofo1ly limiting infectious entity", a conclusion in keepmg WIth I I thank Dr. Frank Lilly for many discussions helpful in the preparation of this manuscript.
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the observation that the titer of its helper is normally much higher than that of SFFV itself (19) . However, in mice restrictive to helper virus expression because of a resistance gene called Fv-l (16), the doseresponse patterns for SFFV expression are "multiplehit" or "two-hit" (text- fig. lA, solid line) (12) (13) (14) .
The Fv-l gene restricts MuL V expression = 103-fold near its dilution endpoint (16) to a level near that of SFFV. Under these conditions, the multiple-hit patterns reflect a requirement for infection of the Fv-I-restrictive cell by at least one (perhaps two) helper virus particle(s) in addition to SFFV for spleen focus formation to occur. A similar requirement for cell infection by a helper MuL V in addition to SFFV may exist for spleen focus formation in Fv-I-susceptible mice, but we cannot be certain of this because of the presence of infectious helper virus in great excess. Thus the defectiveness of SFFV was demonstrated by the restriction of the expression of its helper virus with the aid of the Fv-l gene.
MuSV is also defective for focus formation (17) , but the helper MuL V's native to most MuSV strains [Moloney (20) , Harvey (21) , and Kirsten (22)] are not restricted by either allele of the Fv-l gene (i.e., they are NB-tropic); the defectiveness of MuSV was demonstrated in another way. Foci of piled-up round and spindle-shaped cells induced by MuSV in monolayers of mouse embryo fibroblasts form as a result of virus spread (dependent on coinfection with MuLV) and cell division (independent of coinfection with MuLV). The former mechanism predominated in titrations based on focus counts scored only 3-4 days post infection, whereas the latter mechanism became significant in titrations scored 7 days post infection (23). Because foci scored early gave two-hit titration patterns and those scored later gave one-hit patterns, it was concluded that MuSV is defective for virus replication but not for cell transformation (23). Similar conclusions were reached for Friend SFFV (24) when the generation of tumor cells in the spleens of SFFV-infected, Fv-I-restrictive mice followed a one-hit dose-response pattern, whereas the generation of infectious SFFV in the same mice followed a twohit dose-response pattern. The helper agents in SFFV and MuSV preparations are MuL V's. Early investigations on the isolation of MuLV from SFFV-containing preparations were arduous, for the SFFV had to be removed by serial passage in resistant hosts, i.e., rats or C57BL mice (19, (25) (26) (27) . Later, advantage was taken of the knowledge that MuLV's can be isolated from MuSV preparations by dilution past the endpoint for focus formation (17, 28) or sarcoma induction (29) , and similar studies showed that Friend virus preparations also contain a lymphatic leukemia-inducipg MuL V (19, 30, 31) . 
DIFFERENCES BETWEEN SFFV AND MuSV
The similarities between SFFV and MuSV are remarkable, but they have many important distinguishing features, of which the most obvious is their different pathogenicities. MuSV induces sarcomas in infected mice by transforming fibroblasts (42) and also by evoking a proliferative host response (43); the tumors often regress in immunologically competent hosts (44). Because fibroblasts from mouse embryos can be grown easily in tissue culture, where the~ (o~ cell lines established from them) support the :epll(::atl(~n of MuSV and are rapidly transformed by It, this virus-cell system has been intensively studied in vitro (J 7, 23, 28, 33, 41, 45 ). In contrast, SFFV which replicates in and transforms primitive hema~ topoietic cells in vivo (46-49), grows to such a limited extent in mouse embryo fibroblasts that it is uually lost after three or four passages, and it does not transform these cells at all. In fact, no transformation assay has yet bee~ ~:veloped fo~ SFFV in vitro, probably because prumtIve erythrOid cells could not, until r~cently, be grown and quantitated successfully in tissue culture (50, 51). Consequently, studies on the early interactions between SFFV and its target cells ha,:,e been largely confined to in vivo experiments. ThiS has often made it difficult to distinguish the pathogenic effects of SFFV from those of its helper virus(es) .
Despite this problem, there seems to be little doubt that SFFV indu~e~ the rapid .erythroleukemic syndrome charactenstlc of mice mfected with Friend an~ Rauscher virus preparations. Helper virus preparatIOns cleared of SFFV regularly lack the capacity to induce erythroleukemia (Steeves RA: Unpublished observations), and the dilution endpoint for Friend SFFV coincides with the endpoints for the induction of ~p.lenomegaly. (52) and polycythemia (53). In addition, SFFV-mduced tumors cultivated in vitro retain their capacity for erythroid differentiation (37 54-56) and either continue to release infectiou~ SFFV (55, 56) or retain its genome in a "rescuable" form (35,.37). Any doubts that SFFV induces erythroleukemia .could be ~ased on the probability that SFFV and ItS helper vlrus(es) are symbiotic and on the possibility (though unlikely) that helper virus is qualita~ively different in its pathogenic capacity at titers higher than those regularly observed in helper virus stocks free of detectable SFFV.
Spleen foci might, therefore, be viewed as multifocal sites of origin .of eryt~roleukemic cells. Although t~e bone marrow IS also mvolved very early in the disease (J 8) , the continuing cell invasion and erythr.oPOlesls are confined principally to the spleen and liver (6, 8) , provoking severe enlargement of these organs. ~he blood is characterized by marked erythroblastOSIs and lymphocytosis, and, during the terminal stage of the disease, leukemic cells disseminate throughout the host, especially to the kidneys and lungs (8) .
Though SFFV induces erythroleukemia it does not ah~ays i~duce polycythemia (53). Som~ strains of
Fnend virus complex (called FV-P) contained high titers of SFFV and induced polycythemia vera 3 to 4 weeks. post infection; other strains (called FV-A) con tamed less SFFV and induced anemia, sometimes after many w~eks. Rauscher virus preparations, which usually con tamed less SFFV than our Friend virus preparations, regularly induced anemia. Thus the appare~t association between SFFV titer and polycythemia has to do not with the input dose of SFFV ?ut with the titer of SFFV ultimately reached in the mfected host, and this in turn depends on virus and host factors not yet clearly understood. We will return to the problem of polycythemia later.
The term "erythroleukemia" has been used because the erythropoietic disease induced by the Friend and Rauscher strains of SFFV has a more malignant character than the erythroblastosis described in mice infected with the Harvey and Kirsten strains of MuSV (21, 22, 57, 58) . The capacity to induce spleen foci is unique to SFFV -containing preparations but is lacking in MuSV preparations unless SFFV is present, as it might be in Friend or Rauscher pseudotypes of MuSV. The development of these foci and the associated erythroid response are independent of the hormone erythropoietin (59, 60), which is involved in feedback control of normal erythropoiesis.
Most importantly, cells in spleen foci can grow as tumor colonies in the spleens of unirradiated mice (61, 62). This is compelling evidence that SFFV transforms hematopoietic cells into neoplastic cells. However, one property generally assigned to neoplastic cells is lacking in most, or perhaps all, cells immediately after transformation by SFFV: the property of autonomous growth.
The rapidity with which SFFV transforms cells is unique among MuLV's, and it may even exceed the transformation rate of MuSV. Cells that grow as transplants in the spleens of intravenously inoculated mice have been detected just 2 days after SFFV infection with the spleen colony assay (62), and 3 hours post infection with a radioisotope (125 iododeoxyuridine) assay (63). Although such "early Friend cells" demonstrate a greater proliferative potential than hematopoietic stem cells from normal mice (62-64), their capacity for self-renewal eventually declines (62), in contrast to the truly autonomous nature of established tumor cell lines initiated from mice surviving 1-2 months post infection (65-67). Also, the karyotypes of eady Friend cells are indistinguishable from those of normal mouse cells (68) , whereas cell lines established from late survivors are aneuploid, with up to two similar (55) or dissimilar (68) metacentric chromosomes. Thus there are at least two kinds of SFFV -transformed cells compared with normal hematopoietic colony-forming cells (CFC) in table 1: the differentiating tumor CFC and the autonomous tumor CFC. The former is the dominant cell in early Friend disease, whereas the latter is either rare or absent, and gradually arises from the former, perhaps by tumor "progression" (69) .
An assay for the transforming effect of MuSV was developed in tissue culture (23), in which the transformatiun frequency was 1.4% under optimal condi-tions. Unfortunately, the transforming capaCities of MuSV and SFFV cannot be compared directly, because a transformation assay for the latter does not exist in vitro, and tumors induced by the former in vivo are highly immunogenic (44).
Among SFFV-transformed cells, those that express themselves as tumor colony-forming units (TCFU) increase 50-fold in the spleen and bone marrow of susceptible mice between 2 and 4 days after intravenous infection with SFFV (62). Even with a high dose of virus (e.g., 6,000 FFU) in the inoculum, many uninfected cells would still be available after 2 or 3 days for infection and transformation by progeny SFFV, usually recoverable from the plasma within 3 days of infection at levels equivalent to the input dose (74). Whereas this mechanism may account for some of the increase in TCFU, it is also due to continued growth by self-renewal of the initially transformed cells, as demonstrated by the growth of TCFU on serial transplantation in histocompatible but SFFVresistant hosts (62).
The growth kinetics of TCFU in SFFV-resistant mice have also revealed useful information about later phases of the disease. The total number of TCFU/ spleen increased exponentially for the first 10 days after transplantation, but diminished to 10-2 of the maximum level during the next 10 days (62). However, during this second 10-day period, the spleens continued to increase in total cellularity and the mice developed polycythemia. During the next 30 days, the incidence of splenomegaly and polycythemia declined, as demonstrated by graded numbers of transplanted cells in a similar experiment (table 2) . Recent studies indicate that the kind of regression described here [not to be confused with regression in certain Friend SFFV-infected mice (75-77)] could have been promoted by the greatly reduced survival time of infected erythrocytes (78) and by massive death of less differentiated cells (79) , possibly duc to an autoimmune response (80) .
This sequential development and regression of TCFU, spleen enlargement, and then polycythemia in tumor-grafted but SFFV -resistant mice confirm a much earlier impression (8) b Hybrid resistance n'frrs to tIl(' f(,UU(,(,U colony-forming eilieirilcy of eFt' transplanted into FI hybrids hetween the dOllor strain alHlcertain other mouse strains (7I).
, Decline refers to a gradual loss of colony·forllling ability after 3-4 serial transplantations in irradiated syngeneic hosts (64). ,/ Unless stilllulated hy dilllethyl sulfoxide (54). (82, 83) , and this may contribute to its rapid lethality in adult mice, also in contrast with MuSV. Whereas the helper MuL V in both MuSV and SFFV preparations is immunodepressive by itself, its effects are only transient and not as profound as those of preparations containing SFFV (19) . It is quite possible, however, that a) agents other than SFFV but associated with it are immunodepressive, b) SFFV depresses the host's immune system by one mechanism and stimulates erythropoiesis by yet another, or c) one mechanism suffices to initiate both effects of SFFV.
The last hypothesis is compatible with one of the five possible mechanisms for SFFV-induced immunodepression, the common stem-cell model, described by Dent (82). If we view the "pluripotent" stem cell of the bone marrow (84) as a precursor of both lymphoid and erythroid stem cells (text- fig. 2 ), we might allow SFFV, by the infection of one or several stages of differentiating cells, to cause a significant increase in the fraction of cells entering the erythroid pathway at the expense of the fraction of cells entering the lymphoid pathway. As more and more pluripotent stem cells or their progeny become infected by SFFV in rising titer and as they become committed to erythropoiesis, certain pools of cells along the lymphoid pathway to the B cell and plasma cell become severely depleted, and humoral immunity in the host is compromised (85) .
Two interesting observations also fit this model. First, hyperstimulation of the immune system results in diminished sensitivity to Rauscher SFFV, possibly by exhausting the lymphoid reserves in the bone marrow and reducing potential target cell pools for the virus (86) . Second, a single dose of endotoxin given to mice 4 days before Friend SFFV increases their sensitivity to the virus (87), apparently by triggering the release of a "cohort" of potential target cells from the pluripotent stem-cell pool (cells which, without SFFV infection, might have been destined for the lymphoid pathway). Future experiments that take advantage of our growing understanding of immune mechanisms will help to refute or extend this hypothesis. Still another difference between SFFV and !\[uSV is the genetic control bf host resistance and susceptibility to these viruses. Though the diseases induced by either virus can be influenced by an H-2-associated gene and the Fv-l gene, the Fv-2 gene is specific for the expression of SFFV (16) . Mice homozygous for the recessive resistance allele of Fv-2 are completely refractory to spleen focus formation by SFFV, though they will support the replication of its helper MuL V (19) , and even, to a limited extent, of SFFV itself (Steeves RA, Lilly F: Unpublished observations). This indicates that Fv-2TIT cells can be infected in vivo, in keeping with their lack of resistance to infection in tissue culture (16) , so the Fv-2 gene must inhibit cell transformation or TCFU growth to prevent spleen focus formation. The latter alternative was supported in a recent study (88) which suggested that host cell rejection of TCFU might be involved.
Finally, SFFV and MuSV differ with respect to the specificity of agents which will provide a helper function for them. In addition to MuLV's, which help both viruses,feline leukemia virus (89) and similar viruses from hamsters (90) and rats (91) will increase the focus-forming efficiency of MuSV in tissue culture; this requires the use of non murine cells, however, usually ·cells of the same species from which the helper virm was isolated. In contrast, with the in vivo assay for helpers of SFFV (92), the host species could not be changed without losing sensitivity to SFFV completely, but despite this requirement, helper activity was detected among an even broader range of samples, including extracts of human leukemic spleens (93) , mycoplasmas (94), and several species of bacteria (95) . The reason for this difference is not clear. Though it may have to do with the fact that the assay for SFFV is conducted in vivo, there is no evidence that any of the nonviral helper factors depress the immune system of the host or stimulate its target cells (95) .
Many virus stocks containing SFFV or MuSV also contain the lactic dehydrogenase-elevating virus (LDV) (96) . Whereas LDV can potentiate the oncogenic effects of both viruses (87, 97) , these effects were originally observed only when LDV infection preceded infection with SFFV or MuSV by 2-3 day~, and they were thought to be mediated by stimulating target cells for the virus (87) or by depressing the host's cellular immunity (97) . LDV did not provide helper activity for SFFV in the standard helper assay (92) . In more recent studies, however, removal of LDV from a Rauscher virus preparation reduced its pathogenicity significantly, and replacement of LDV into the "uncontaminated" Rauscher virus pool restored its activity (98, 99) . This does not exclude the possibility of a target cell or immunodepressive effect of LDV, but it does raise again the question of the possible role of LDV as a helper virus for SFFV.
RELATIONSHIP BETWEEN FRIEND SFFV AND RAUSCHER SFFV
Though there is little doubt that the antigenicities of their native helper MuL V's arc distinct from one another (39, 100), no precise marker has yet been used to compare the SFFV in the Friend and Rauscher virus complexes. The Rauscher virus complex differs from most of the Friend strains by not inducing polycythemia and by inducing extensive splenic necrosis and the development of blood-filled sacs in the spleen in susceptible mouse strains. These differences do not seem related to differences in SFFV titer, and the two strain designations should probably be retained, perhaps also for historical reasons, until a detailed comparison of the SFFV genome in each preparation becomes feasible.
TERMINOLOGY PROPOSED
To be aware of the complexity of Friend and Rauscher leukemia virus preparations is admirable and relatively easy, but to communicate effectively by the clear identification of the particular virus in the complex under consideration is necessary and often difficult without a logical terminology. Among the defective RNA tumor viruses, terminology ha~ been most successful in the avian system (5), except, perhaps, for avian sarcoma virus itself (usually abbreviated RSV rather than AvSV). Here, the memory of Peyton Rous is indelibly imprinted on our minds.
In the murine system, the term ~fuSV was gradually accepted, once several strains [Moloney (M), Harvey (H), and Kirsten (Ki)] came into common use. How logical it is, then, to write Friend SFFV (F-SFFV) and Rauscher SFFV (R-SFFV), just as one writes Schmidt-Ruppin RSV (SR-RSV) or Harvey MuSV (H-MuSV), with the helper virus assumed to be the native one unless indicated otherwise (table 3) 
